Research supported by:
Why Early Detection
To treat a disease, we must first know the condition exists. The earlier, the better.
Biomarker testing helps accelerate innovation for personalized treatment.
Lewy Body Dementia Test
Often, people with LBD encounter a difficult diagnostic journey. Our game-changing SYNTapⓇ Biomarker Test helps doctors make accurate LBD diagnoses.
Parkinson’s Test
Our breakthrough SYNTapⓇ Biomarker Test helps doctors more accurately diagnose Parkinson’s disease.
How It Works
We track the prion-protein biomarkers associated with Alzheimer’s, Parkinson’s, Lewy Body Dementia, and other brain diseases.
Biomarker testing is the keystone for the cure.
Alzheimer’s & Parkinson’s - A Crushing Public Health Crisis
Today, 5 million people in the US are diagnosed with Alzheimer’s, and 1 million with Parkinson’s. These numbers are expected to triple by 2050.
Despite billions spent on drug development, there’s no cure in sight.
Make an Impact!
Be a Part of Big Brain Research
Every Alzheimer’s, Parkinson’s, and LBD patient is unique. To better care for each individual, we need personalized treatment.
Molecular diagnosis helps doctors gain insight into the person’s biomarker profile, advancing science to precision medicine.
Every Alzheimer’s, Parkinson’s, and LBD patient is unique. To better care for each individual, we need personalized treatment.
Molecular diagnosis helps doctors gain insight into the person’s biomarker profile, advancing science to precision medicine.
Claudio Soto, CoFounder & CSO
Claudio Soto, CoFounder & CSO
